BRII BIOSCIENCES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.28 HKD | 0.00% |
|
+2.40% | -43.86% |
| Mar. 25 | Transcript : Brii Biosciences Limited, 2023 Earnings Call, Mar 25, 2024 | |
| Mar. 22 | Brii Biosciences Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2023 | 417M 57.69M 451M | Sales 2024 * | - | Capitalization | 863M 120M 934M |
|---|---|---|---|---|---|
| Net income 2023 | -175M -24.22M -189M | Net income 2024 * | -575M -79.59M -622M | EV / Sales 2023 | 2.46 x |
| Net cash position 2023 | 486M 67.34M 526M | Net cash position 2024 * | 956M 132M 1.03B | EV / Sales 2024 * | - |
| P/E ratio 2023 |
-8.63
x | P/E ratio 2024 * |
-1.57
x | Employees | 128 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 80.51% |
More Fundamentals
* Assessed data
More news
Latest transcript on Brii Biosciences Limited
More press releases
| 1 week | +2.40% | ||
| Current month | +2.40% | ||
| 1 month | +36.17% | ||
| 3 months | -27.68% | ||
| 6 months | -59.37% | ||
| Current year | -43.86% |
1 week
1.24
1.43
1 month
0.851.43
Current year
0.852.39
1 year
0.854.24
3 years
0.8552.60
5 years
0.8552.60
10 years
0.8552.60
| Managers | Title | Age | Since |
|---|---|---|---|
Zhi Hong
CEO | Chief Executive Officer | 60 | 17-12-07 |
An Kang Li
DFI | Director of Finance/CFO | 47 | 20-08-31 |
David Margolis
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gregg Alton
BRD | Director/Board Member | 58 | 21-06-21 |
Tai Yin Yang
BRD | Director/Board Member | 70 | 22-08-31 |
Robert Nelsen
BRD | Director/Board Member | 60 | 18-06-21 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.53% | 4 M€ | -27.92% | ||
| 0.00% | 4 M€ | -4.41% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 1.28 | 0.00% | 1 389 500 |
| 24-05-07 | 1.28 | +0.79% | 1,990,000 |
| 24-05-06 | 1.27 | -7.97% | 2,814,000 |
| 24-05-03 | 1.38 | +0.73% | 3,114,500 |
| 24-05-02 | 1.37 | +9.60% | 3,063,000 |
Delayed Quote Hong Kong S.E., May 08, 2024 at 04:08 am EDT
More quotes
Brii Biosciences Ltd is a biotechnology company based in China and the United States principally engaged in developing therapies for infectious diseases. The Companyâs products are applied in infectious diseases, such as hepatitis B virus (HBV), human immunodeficiency virus (HIV), multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases, which have significant public health burdens. The Company is also developing therapies for COVID-19 and other diseases.
Calendar
2024-06-24
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.183
CNY
Average target price
4.314
CNY
Spread / Average Target
+264.55%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -43.86% | 119M | |
| +3.71% | 106B | |
| +7.02% | 23.47B | |
| -14.83% | 21.9B | |
| -7.05% | 18.77B | |
| -38.55% | 17.85B | |
| -8.28% | 16.78B | |
| +6.53% | 14.41B | |
| +35.22% | 12.86B | |
| +316.44% | 8.78B |
- Stock Market
- Equities
- 2137 Stock